Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
Launched by ROSWELL PARK CANCER INSTITUTE · Mar 22, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special program to improve quality of life can help patients with early-stage lung cancer make better decisions about their treatment. Specifically, it focuses on patients who can choose between having surgery or a type of radiation therapy called stereotactic body radiation therapy (SBRT). The goal is to provide patients with helpful information about how each option might affect their quality of life, which may lead to less regret about their choices and greater satisfaction with their care.
To participate in this study, you need to be at least 18 years old and diagnosed with stage I or II non-small cell lung cancer, which is a common type of lung cancer. You must be eligible for both surgery and SBRT and able to understand and sign consent forms in English. If you join, you can expect to receive information that may help you feel more confident in making your treatment decision. It’s important to note that this trial is currently recruiting participants, and it excludes those with more advanced lung cancer or other specific conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years
- • Radiographic stage I-II non-small cell lung cancer (NSCLC)
- • Eligible for both surgery and SBRT
- • Able to provide informed consent in English
- • Have verbal fluency in English
- • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- Exclusion Criteria:
- • Radiographic stage III-IV NSCLC
- • Eligible for either only surgery or SBRT, but not both
- • Eligible for palliative-intent treatments or supportive care only.
- • Pregnant female participants.
- • Unwilling or unable to follow protocol requirements
- • Any condition which in the investigator's opinion deems the participant an unsuitable candidate
- • Cognitively impaired adults/adults with impaired decision-making capacity
- • Individuals who are not yet adults (infants, children, teenagers)
- • Prisoners
About Roswell Park Cancer Institute
Roswell Park Cancer Institute is a leading biomedical research and treatment center dedicated to advancing cancer care through innovative research, education, and patient-centered clinical services. Established in 1898, it is recognized for its pioneering contributions to cancer research and treatment, making significant strides in immunotherapy, precision medicine, and cancer prevention. With a commitment to translating scientific discoveries into effective therapies, Roswell Park conducts a wide range of clinical trials aimed at improving outcomes for cancer patients. Its multidisciplinary team of experts collaborates to provide comprehensive care while fostering an environment of discovery and hope for patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buffalo, New York, United States
Patients applied
Trial Officials
Anurag K Singh
Principal Investigator
Roswell Park Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials